His main research concerns Internal medicine, Immunology, Gastroenterology, Hepatitis C virus and Hepatitis C. His Internal medicine study incorporates themes from Coinfection, Efavirenz and Nevirapine. His research ties Acquired immunodeficiency syndrome and Immunology together.
His work carried out in the field of Acquired immunodeficiency syndrome brings together such families of science as Logistic regression, Malignancy, T cell, Circulating MicroRNA and Case-control study. His Hepatitis C virus research incorporates themes from Odds ratio and Viral disease. His biological study spans a wide range of topics, including Viral hepatitis and Immunopathology.
Luz Martín-Carbonero focuses on Internal medicine, Immunology, Gastroenterology, Virology and Hepatitis C virus. His studies in Internal medicine integrate themes in fields like Coinfection and Ribavirin. His research is interdisciplinary, bridging the disciplines of Acquired immunodeficiency syndrome and Immunology.
Luz Martín-Carbonero usually deals with Gastroenterology and limits it to topics linked to Atazanavir and Pharmacology. When carried out as part of a general Virology research project, his work on Lamivudine, Viral load, Hepatitis B virus and Virological response is frequently linked to work in Drug resistance, therefore connecting diverse disciplines of study. His Hepatitis C virus research includes themes of Interferon, Adverse effect, Pediatrics and Alanine transaminase.
His primary scientific interests are in Internal medicine, Virology, Hepatitis C, Lamivudine and Immunology. His Internal medicine study combines topics in areas such as Gastroenterology, Viral suppression and Viral load. His work in the fields of Hepatitis and Hepatitis C virus overlaps with other areas such as Chemistry and Exosome.
His Hepatitis C research integrates issues from Psychiatry, Psychopathology, Depression, Anxiety and Virological response. Luz Martín-Carbonero has included themes like Dolutegravir, Resistance mutation, Discontinuation and Cohort in his Lamivudine study. His research links Malignancy with Immunology.
His primary areas of study are Internal medicine, Immunology, Lamivudine, Telomerase and Viral load. He interconnects Ribavirin and Hepatitis C virus in the investigation of issues within Internal medicine. His Immunology study frequently links to other fields, such as Malignancy.
His work carried out in the field of Lamivudine brings together such families of science as Clinical trial, Discontinuation, Dolutegravir, Integrase inhibitor and Resistance mutation. Luz Martín-Carbonero combines subjects such as Reverse-transcriptase inhibitor, Prospective cohort study, Cohort and Abacavir with his study of Viral load. His studies deal with areas such as Reverse transcriptase and Confounding as well as Oncology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study
Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka.
PLOS ONE (2015)
Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.
Marina Núñez;Raquel Lana;Juan Luis Mendoza;Luz Martín-Carbonero.
Journal of Acquired Immune Deficiency Syndromes (2001)
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study.
Luz Martín-Carbonero;Yves Benhamou;Massimo Puoti;Juan Berenguer.
Clinical Infectious Diseases (2004)
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.
Pablo Labarga;Pablo Barreiro;Luz Martin-Carbonero;Sonia Rodriguez-Novoa.
Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients.
Luz Martín-Carbonero;Vincent Soriano;Eulalia Valencia;Javier García-Samaniego.
AIDS Research and Human Retroviruses (2001)
Pegylated Ifn-α2b plus ribavirin as therapy for chronic hepatitis C in Hiv-infected patients
Mayte Pérez-Olmeda;Marina Núñez;Miriam Romero;Juan González.
Hepatotoxicity of Antiretroviral Drugs Is Reduced after Successful Treatment of Chronic Hepatitis C in HIV-Infected Patients
Pablo Labarga;Vicente Soriano;María Eugenia Vispo;Javier Pinilla.
The Journal of Infectious Diseases (2007)
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.
Sonia Rodríguez-Nóvoa;Luz Martín-Carbonero;Pablo Barreiro;Gema González-Pardo.
Severe liver disease associated with prolonged exposure to antiretroviral drugs.
Ivana Maida;Marina Núñez;Maria Jose Ríos;Luz Martín-Carbonero.
Journal of Acquired Immune Deficiency Syndromes (2006)
Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine.
Luz Martín-Carbonero;Marina Núñez;Juan González-Lahoz;Vincent Soriano.
Hiv Clinical Trials (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: